|
Session 8: Hormone Considerations in Transgender Patients with Gynecologic Cancer |
|
Enduring |
|
$0.00 |
|
Management of Chemotherapy Hypersensitivity Reactions and Desensitization: An SGO Clinical Practice Statement |
|
Enduring |
|
$0.00 |
|
Eradicating Racism and Discrimination in Medicine (Session from SGO 2021 Annual Meeting) |
|
Enduring |
|
$0.00 |
|
SGO Journal Club On-Demand: The ABCs of ADCs |
|
Enduring |
|
$0.00 |
|
Updates and Highlights from Summer NRG Oncology 2023 |
|
Enduring |
|
$0.00 |
|
Express Coding Webinar: Coding Complex Surgical Cases |
|
Enduring |
|
$0.00 |
|
SGO Taskforce for Board Certification Support: Ovarian Cancer Resources - Preparing for the ABOG Oral Board Exam (Pt. 4) |
|
Enduring |
|
$0.00 |
|
Molecular Target: Human Epidermal Growth Factor Receptor 2 (HER2) |
|
Enduring |
|
$0.00 |
|
Infusion Confusion: COVID-19 and Anti-Cancer Treatments and Clinical Trial Considerations for Gynecologic Oncology Patients |
|
Enduring |
|
$0.00 |
|
Your Unique Story: What Do Survivors Experience During Surveillance? |
|
Enduring |
|
$0.00 |
|
Gestational Trophoblastic Neoplasia (GTN) Education Module |
|
Enduring |
|
$15.00 |
|
Sentinel Nodes |
|
Enduring |
|
$0.00 |
|
PARP Inhibitors: A Practical Approach to Selection and Management |
|
Enduring |
|
$0.00 |
|
Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets |
|
Enduring |
|
$0.00 |
|
The Future is Now: Determining the Fate of Gynecologic Oncology |
|
Enduring |
|
$0.00 |
Facebook
Twitter
LinkedIn
Forward